Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension.
Catherine E Simpson, Anjira S Ambade, Robert Harlan...
https://pubmed.ncbi.nlm.nih.gov/37786941/Actively Recruiting
Led by Pulmonary Hypertension Association, Inc. · Updated on 2025-11-14
3000
Participants Needed
52
Research Sites
N/A
Total Duration
Researchers are collecting information on people with pulmonary arterial hypertension PAH and chronic thromboembolic pulmonary hypertension CTEPH through the Pulmonary Hypertension Association Registry PHAR. This study aims to understand how these patients are evaluated, diagnosed, and treated at specialized Pulmonary Hypertension Care Centers across the U.S. It also looks at how well patients do over time and whether care follows recommended guidelines, with a goal to identify factors influencing patient outcomes. Participants include those with newly diagnosed or existing PAH or CTEPH, as well as pediatric patients with Group 3 pulmonary hypertension related to developmental lung disease, all within six months of their first outpatient visit to a PH Care Center. The registry collects detailed data including diagnosis, clinical status, socioeconomic factors, test results, treatments, and social history. Participants are followed over time to update changes in therapy, hospital visits, and survival. Throughout the study, participants provide ongoing information on their health status and treatments. Researchers collect data on diagnosis tests, therapy changes, hospitalizations, and survival rates over a 10-year period. The registry helps monitor adherence to guidelines and evaluates clinical predictors of disease progression. This long-term observation may improve care by highlighting effective treatment practices and patient outcomes.
CONDITIONS
Pulmonary Hypertension Association Registry
E
Elizabeth Joseloff, PhD
C
Charles D Burger, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pulmonary Hypertension Association, Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants who have been diagnosed with pulmonary hypertension are observed over time to collect data on their health and disease progression.
Periodic visits depending on clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Catherine E Simpson, Anjira S Ambade, Robert Harlan...
https://pubmed.ncbi.nlm.nih.gov/37786941/Anna R Hemnes, Jane A Leopold, Milena K Radeva...
https://pubmed.ncbi.nlm.nih.gov/35953136/Mario Naranjo, Erika B Rosenzweig, Anna R Hemnes...
https://pubmed.ncbi.nlm.nih.gov/37614830/Amber McCormick, Amita Krishnan, David Badesch...
https://pubmed.ncbi.nlm.nih.gov/36787969/Robert P Frantz, Jane A Leopold, Paul M Hassoun...
https://pubmed.ncbi.nlm.nih.gov/36618713/Christine L Jellis, Margaret M Park, Aiden Abidov...
https://pubmed.ncbi.nlm.nih.gov/34097027/Pieter Martens, Shilin Yu, Brett Larive...
https://pubmed.ncbi.nlm.nih.gov/36879444/Megan M Lowery, Nicholas S Hill, Lu Wang...
https://pubmed.ncbi.nlm.nih.gov/37968017/Franz P Rischard, Roberto J Bernardo, Rebecca R Vanderpool...
https://pubmed.ncbi.nlm.nih.gov/37664964/W H Wilson Tang, Jennifer D Wilcox, Miriam S Jacob...
https://pubmed.ncbi.nlm.nih.gov/32088984/Pulmonary Hypertension Association, Inc.
Lead Sponsor